CNS Anticancer Drug Discovery and Development Conference

Transcription

1 CNS Anticancer Drug Discovery and Development Conference November 12-13, 2014 Loews Hotel, Miami Beach, Florida Hosted by the Society for Neuro-Oncology

2 The Society for Neuro-Oncology gratefully acknowledges the following sponsors for their support of this program. GOLD SILVER BRONZE Found from website recreate PMS

3 CNS Anticancer Drug Discovery and Development Conference November 12-13, 2014 Loews Hotel, Miami Beach, Florida Hosted by the Society for Neuro-Oncology CONFERENCE CHAIR Victor A. Levin, MD Clinical Professor, Department of Neurosurgery, UCSF; Emeritus Professor, Department of Neuro-Oncology, UT M.D. Anderson Cancer Center; Department of Neurosurgery and Neuroscience, Kaiser Permanente ORGANIZING AND SCIENTIFIC PROGRAM COMMITTEE MEMBERS Stephen L. Eck, MD, PhD Vice President, Global Head of Medical Oncology, Astellas Pharma Global Development William Elmquist, PhD Chair, Department of Pharmaceutics, University of Minnesota James M. Gallo, PhD Professor, Dept. of Pharmacology and Systems Therapeutics, Icahn School of Medicine at Mount Sinai Timothy Heffron, PhD Senior Scientist, Discovery Chemistry, Genentech Research Alan Olivero, PhD Senior Director, Discovery Chemistry, Genentech Research and Early Development Jann Sarkaria, MD Associate Professor, Department of Radiation Oncology, Mayo Clinic Beverly Teicher, PhD Chief, Molecular Pharmacology Branch, National Cancer Institute

4 Wednesday, November 12, 2014 CNS Anticancer Drug Discovery and Development Conference 8:00am 8:30am 8:30am - 11:55am 8:40am 9:05am 9:30am 9:50am 10:30am 10:40am 10:57am 11:14am 11:55am 12:45pm - 2:40pm 12:45pm 1:00pm 1:20pm 1:35pm Continental Breakfast Welcome and Introduction Victor A. Levin, MD Program Chair SESSION 1: PHARMACOLOGICAL CHALLENGES Therapy for Gliomas and Medulloblastoma: Reflection on a Life s Work in Experimental Therapeutics and Drug Discovery/Development Victor A. Levin, MD University of California, San Francisco; Emeritus Professor, MD Anderson Cancer Center; Kaiser Permanente Impact of Blood brain Barrier on Tumors and Drugs Quentin Smith, PhD Texas Tech University School of Pharmacy Impact of Endothelial Efflux Pumps and Cellular Protective Mechanisms on Drugs William Elmquist, PhD University of Minnesota School of Pharmacy Impact of Drug target Binding Kinetics on Drug Action: Principles and Practice Peter Tonge, MD, PhD Stony Brook University Break AB38- The Critical Influence of the Blood brain Barrier (BBB) on the Success of Individualized Medicine in Glioblastoma Multiforme (GBM) Jann Sarkaria, MD Mayo Clinic AB16- Heterogeneous Permeability, Drug Uptake, and Ffficacy in MCF7 and MDA MB 231 Intracranial and Subcutaneous Xenograft Models Ramakrishna Samala, PhD Texas Tech University Health Sciences Center Moderator: Kurt Jaeckle, MD Mayo Clinic Lunch SESSION 2: RECENT DRUG APPROACHES Irreversible Kinase Inhibitors in Cancer Russell Petter, PhD Celgene Design and Development of Reversible P13K Inhibitor Timothy Heffron, PhD Genentech, Inc. Design and Development of Irreversible EGFR Inhibitor Wang Shen, PhD Kanion USA, Inc. AB03: Discovery of PF , a Macrocyclic Inhibitor of ALK and ROS1 Kinases with Preclinical Brain Availability and Broad Spectrum Potency Against ALK resistant Mutations Ted Johnson, PhD Pfizer

5 Wednesday, November 12, 2014 CNS Anticancer Drug Discovery and Development Conference 1:50pm 2:10pm 2:40pm 2:55pm - 5:00pm 2:55pm 3:15pm 3:35pm 3:55pm 4:15pm 4:35pm 5:00pm - 7:00pm Large Molecule Peptide Conjugated Drugs Jean Lachowicz, PhD Angiochem, Inc. Moderator: Alan Olivero, PhD Genentech Break SESSION 3: DRUG TARGETS AND DISCOVERY Functional Genomics to Identify Novel Druggable Targets in Glioblastoma Antonio Iavarone, MD Columbia University Institute for Cancer Genetics Next Generation Drug Discovery for Glioblastoma Using Functional Genetics, Patient Isolates, and BBB Traversing Optide Libraries Patrick Paddison, PhD Fred Hutchinson Cancer Research Center Kinase Chemical Genetics and Cancer Drug Discovery Arvin Dar, PhD Icahn School of Medicine at Mount Sinai Proteomics for the Identification of Targets and Quantification of Therapeutic Efficacy Forest White, PhD Massachusetts Institute of Technology Systems Pharmacology Approaches to Inform AntiCancer Drug Discovery/Development and Personalized Therapy Marc Birtwistle, PhD Icahn School of Medicine at Mount Sinai Moderator: Jann Sarkaria, MD Mayo Clinic Reception

6 Thursday, November 13, 2014 CNS Anticancer Drug Discovery and Development Conference 8:30am 9:00am - 11:15am 9:00am 9:25am 9:50am 10:30am 11:15am - 12:30pm 11:15am 11:27am 11:39am 11:51am 12:03pm 12:30pm 1:15pm - 2:40pm 1:15pm 1:27pm Continental Breakfast SESSION 4: CLINICAL PATHS Endpoints for Clinical Trials - Clinicians Perspective Patrick Wen, MD Dana-Farber Cancer Institute Endpoints for Clinical Trials - FDA Perspective Joohee Sul, MD US Food and Drug Administration Statistical Considerations for Single Agent and Combinations That are Relevant to Regulatory Agencies and Clinical Decision-making Donald Berry, PhD MD Anderson Cancer Center Moderator: Victor Levin, MD Patrick Wen, Joohee Sul, Donald Berry, Timothy Cloughesy and Michael Weller SESSION 5: NOVEL DRUG DELIVERY APPROACHES AB21 Optimized Therapeutic Nanoparticle Delivery of Immune Modulatory MiRNA in Preclinical Murine Models of Malignancy Amy Heimberger, MD MD Anderson Cancer Center AB49 Stem Cell Based Therapies to Treat Resistant and Recurrent Brain Tumors Khalid Shah, PhD Massachusetts General Hospital/Harvard Medical School AB51 Targeting Mitotic Kinesins to Inhibit Proliferation and Invasion of Glioblastoma Stem Cells Monica Venere, PhD Cleveland Clinic AB34 Inhalational Therapy of NEO100 for the Treatment of Recurrent Malignant Gliomas: Upcoming Phase I/IIa Trial Thomas Chen, MD, PhD University of Southern California Moderator: William Elmquist, PhD University of Minnesota Lunch SESSION 6: NEW AGENTS AND NOVEL TARGETS AB30 Arylsulfonamides Inhibit Glioma Growth and HIF Binding to Transcription Co factors P300/CBP Erwin Van Meir, PhD Winship Cancer Center, Emory University AB60 Genome Wide ShRNA Library Screening as a High Throughput Strategy for Discovery of Druggable Targets for Sensitizing Temozolomide in Glioblastoma Gaspar Kitange, MD, PhD Mayo Clinic

7 Thursday, November 13, 2014 CNS Anticancer Drug Discovery and Development Conference 1:39pm 1:51pm 2:03pm 2:15pm 2:40pm 2:50pm - 4:15pm 2:50pm 3:02pm 3:14pm 3:26pm 3:38pm 3:50pm 4:15pm 4:20pm AB09 Targeting Glioma derived Integrin Ligands as a Novel Therapeutic Approach Bozena Kaminska, PhD Nencki Institute of Experimental Biology AB14 Cleavage of Procaspase 3 and Activation of Apoptosis by a Small Molecule Shows Preclinical Promise in Intracranial Models of Glioblastoma Gregory Riggins, MD, PhD Johns Hopkins University AB41 PENAO: a Potent Mitochondrial Targeted Inhibitor for Glioblastoma Moderator: Sylvia Chung, MSc University of New South Wales Moderator: James Gallo, PhD Mount Sinai Medical Center Break SESSION 7: KINASE INHIBITOR AND PROTEOMICS APPROACHES TO TARGETED TREATMENTS AB18 Efficacy of Palbociclib, a Cdk4/6 Inhibitor, in the Treatment of Pediatric Patient derived Xenograft Brain Tumors Michelle Cook-Sangar, VMD, PhD Fred Hutchinson Cancer Research Center AB12 Bypassing Glioblastoma Resistance to EGFR Inhibitors by Synthetic Lethality Clark Chen, MD, PhD University of California, San Diego AB40 Activity of the GlaxoSmithKline Kinase Inhibitor Set on Glioblastoma Stem Cells Simon Khagi, MD Tufts Medical Center AB07 Patient derived Xenografts Mirror the Proteomic Profile of Human Glioblastoma: Implications for Personalized Drug Development Madan Kwatra, PhD Duke University AB19 Using a Proteomics Approach to Identify Potential Therapeutic Targets in Temozolomide resistant Glioblastoma Multiforme Gilberto K.K. Leung, MBBS, PhD The University of Hong Kong Moderator: Timothy Heffron, PhD Genentech Closing Remarks Victor A. Levin, MD Adjourn

8 Society for Neuro-Oncology 4617 Birch Street, Bellaire, TX Tel: E-Fax: